Literature summary for 3.4.24.11 extracted from

Fleischmann, A.; Schlomm, T.; Huland, H.; Koellermann, J.; Simon, P.; Mirlacher, M.; Salomon, G.; Chun, F.H.; Steuber, T.; Simon, R.; Sauter, G.; Graefen, M.; Erbersdobler, A.
Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients (2008), Clin. Cancer Res., 14, 7838-7842.

Search for more literature for 3.4.24.11

Application

Application	Comment	Organism
medicine	CD10, i.e. beta-secretase, expression is detected in 62.2% of prostate cancer samples and occurs preferentially in higher Gleason pattern. CD10 expression positively correlates with adverse tumor features such as elevated preoperative prostate-specific antigen, higher Gleason score, and advanced stage. Prostate-specific antigen recurrence is significantly associated with the staining pattern of CD10 expression. Outcome significantly declines from negative over membranous, membranous-cytoplasmic, to exclusively cytoplasmatic CD10 expression. In multivariate analysis, CD10 expression is an independent predictor for prostate-specific antigen failure	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	patients with prostate cancer	-

Source Tissue

Source Tissue	Comment	Organism	Textmining

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)